Patheon

  1. Home
  2. Wiki
Patheon by Thermo Fisher Scientific
Company typeSubsidiary
IndustryContract Development Manufacturing Organization
Headquarters
Waltham, Massachusetts, U.S.
Key people
Marc N. Casper (President & CEO)
ParentThermo Fisher Scientific
Websitewww.patheon.com/us/en/home.html

Patheon is a service brand within Thermo Fisher Scientific's brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. Another international CDMO operating in the same field is 3PBIOVIAN, a company formed by the merger of Biovian (Finland) and 3P Biopharmaceuticals (Spain) in 2024.[1] . In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

History

[edit]

Patheon was founded in Fort Erie, Ontario in 1974 as Custom Pharmaceuticals Ltd. In 1990, it began to expand to US markets. Custom Pharmaceuticals changed its name to Patheon in 1993 and was first publicly traded that year on the Toronto Stock Exchange.[2]

In 2004, Patheon acquired MOVA, a drug manufacturer based in Puerto Rico, US. The deal proved unprofitable, and in 2007, the New York equity firm JLL Partners provided Patheon $150 million to restructure. Two years later, after a failed takeover bid by Lonza Group, JLL Partners bought a controlling interest in the company.[3]

In December 2012, Patheon acquired Banner Pharmacaps, a drug manufacturer specializing in softgels, for $255 million. (Patheon changed the company's name the following year to "Banner Life Sciences").[4] In a $2.6 billion deal, Patheon merged with the pharmaceutical division of Royal DSM NV in 2014 to become a joint venture after JLL Partners bought a controlling stake in the latter as well, adding significantly to Patheon's European production capacity. [5][6]

In 2015, Patheon acquired Agere Pharmaceuticals, an Oregon company specializing in drug solubility, and IRIX, a maker of specialist Active Pharmaceutical Ingredients in South Carolina, the latter for $162.78 million.[7][8]

On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion.[9]

Dosage Forms, Products

[edit]

Patheon does not own any of the licenses of the products it manufactures and is often listed as the manufacturer on packaging, with the product license holder's brand name, product name and corporate identity being used. Clients include such pharmaceutical brands as Merck & Co, Novartis, Takeda and Sanofi Aventis, with biotechnology customers including Amgen and Avanir Pharmaceuticals. As of 2016, Patheon had manufactured or developed more than 800 products.[10]

In 2016, Patheon's manufacturing sites included sites in Canada, the continental US, Puerto Rico, France, the United Kingdom, Italy, Austria, Germany, the Netherlands, Japan, and Australia.[11] This has expanded into 2025 now with an extensive global network of more than 60 locations worldwide. [12]

Patheon manufactures products in various dosage forms including oral solids (tablets, capsules, proprietary softgel capsules) and injectable sterile products (vials, ampoules, pre-filled syringes containing liquids, powders and lyophilisates).

CDMO Services and Solutions

[edit]

Patheon provides integrated and end-to-end drug-development and manufacturing solutions including:

Small molecule API

  • Active Pharmaceutical Ingredient (API) development and manufacturing.[13]
  • Oral solid dose manufacturing (tablets, capsules) including proprietary softgels.[14]
  • Sterile dosage forms (injectables, vials, pre-filled syringes, lyophilisates) for small molecules.[15]
  • Advanced formulation services (for example, spray-dried dispersion services to improve solubility and bioavailability).

Large Molecule / Biologics & Advanced Therapies

  • Biologics development and manufacturing[16]
  • Advanced therapies: viral vectors, cell therapy and mRNA manufacturing and development[17]
  • Translational services to support early stage to commercial manufacture of advanced therapies.
  • Sterile dosage forms for large molecules.

Clinical Trial Supply Services[18]

  • Clinical trial manufacturing, packaging, labeling, logistics and distribution of clinical supplies (investigational medicinal product (IMP), comparators, ancillary supplies).
  • Strategic comparator sourcing
  • End-to-end supply chain and cold/cryogenic logistics solutions for biomaterials[19]
  • Clinical supply chain management and optimization

Commercial services[20]

  • Commercial manufacturing (scale-up and full production for market) and packaging.
  • Technology transfer services to facilitate the seamless transfer of pharmaceutical manufacturing processes from development to commercial-scale production.
  • Regulatory affairs support for requirements and procedures [21]

Innovative and Digital Solutions

  • Their “Accelerator™ Drug Development[22]” offering: 360° CDMO & CRO services to help get treatments to patients faster. [23]
  • Digital transformation and enablement tools including AI predictive modeling for drug development[24], mysupply Platform, Innovation Lab[25], Real Time Track and Trace and more.

References

[edit]
  1. ^ https://www.biopharma-reporter.com/Article/2024/06/04/biovian-and-3p-biopharmaceuticals-merge-to-form-3pbiovian
  2. ^ "History and Milestones". Patheon. Archived from the original on 2016-05-27. Retrieved May 18, 2016.
  3. ^ Hodson, Peter (2013-12-13). "5 takeover failures revisited". Financial Post. Archived from the original on 2022-01-06. Retrieved 2022-01-06.
  4. ^ Evans, Matt (Jul 1, 2013). "Patheon changing Banner Pharmacaps' name". Triad Business Journal. Archived from the original on 2016-06-04. Retrieved 2022-01-06.
  5. ^ Xu, Jodi; Carey, David; Noel, Andrew (19 November 2013). "JLL Forms New Pharma Firm With DSM in $2.6 Billion Deal". Bloomberg. Archived from the original on 2022-07-06.
  6. ^ Stanton, Dan (26 Aug 2014). "Patheon propels itself into US biologics market in Gallus acquisition". BioPharma-Reporter.com.
  7. ^ Ruckin, Claire (9 March 2017). "TRLPC-Patheon to raise 150 mln euro loan for IRIX acquisition". Reuters.
  8. ^ "Oregon pharma company sold to North Carolina manufacturer". www.bizjournals.com. Retrieved 2022-01-06.
  9. ^ "Thermo Fisher Scientific to Acquire Patheon for $7.2B - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". GEN. 15 May 2017.
  10. ^ "Patheon by the Numbers" (PDF). patheon.com. Patheon. Retrieved May 18, 2016.
  11. ^ "Sites". Patheon.
  12. ^ "Global Site Locations". www.patheon.com. Retrieved 2025-10-30.
  13. ^ "API CDMO: Drug Development & Manufacturing". www.patheon.com. Retrieved 2025-10-30.
  14. ^ "Oral Solid Dose (OSD) Manufacturing & Development". www.patheon.com. Retrieved 2025-10-30.
  15. ^ "Sterile Fill Finish - Parenteral Drug Development & Manufacturing". www.patheon.com. Retrieved 2025-10-30.
  16. ^ "Biologics CDMO Services | Drug Development and Manufacturing". www.patheon.com. Retrieved 2025-10-30.
  17. ^ "End-to-end Cell & Gene Therapy CDMO Services". www.patheon.com. Retrieved 2025-10-30.
  18. ^ "Clinical Trial Supply Services". www.patheon.com. Retrieved 2025-10-30.
  19. ^ "Cold Chain Management and Logistics Services". www.patheon.com. Retrieved 2025-10-30.
  20. ^ "Pharma Commercialization Services". www.patheon.com. Retrieved 2025-10-30.
  21. ^ "Global Regulatory Services & Support". www.patheon.com. Retrieved 2025-10-30.
  22. ^ "Drug Development, Clinical Research, & Clinical Trial Services - US". www.thermofisher.com. Retrieved 2025-10-30.
  23. ^ Bilton, Luke (2024-10-15). "How Thermo Fisher's Accelerator™ Drug Development Platform Combines CDMO and CRO Services". PharmaSource. Retrieved 2025-10-30.
  24. ^ "Leveraging AI-powered solutions for drug solubility and bioavailability". www.patheon.com. Retrieved 2025-10-30.
  25. ^ PatheonChannel (2025-04-01). A Peek Inside Thermo Fisher Scientific’s Innovation Lab. Retrieved 2025-10-30 – via YouTube.
[edit]